Skip to content
PodParley
GLP-1 Daily podcast artwork

PODCAST · health

GLP-1 Daily

by GLP-1 Daily — Lantern Podcasts

You're on a GLP-1 — or you're about to start one — and you don't have time to sift Facebook groups, press releases, and breathless headlines to figure out what actually changed today. GLP-1 Daily does that in eight minutes every weekday morning. Anchor Cassidy separates real label changes from pharma spin, while cohost Silvara tracks the cost and access story: prior authorization walls, employer-plan shifts, compounding-pharmacy enforcement, and who keeps getting left out of the semaglutide and tirzepatide conversation. We cover FDA decisions, clinical trial readouts, supply and shortage updates, and safety or side-effect news — everything framed around one question: does this change what you should ask your clinician today? Every efficacy figure is cited; company-reported data is flagged as such. We skip celebrity weight-loss content, before-and-after photos, and uncited miracle claims. If you take Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or any oral GLP-1 agonist, this is your

Publisher-supplied feed metadata · PodParley refreshed Sep 26, 2026 · Source feed

Subscribe · 0 Bookmark

Episodes

  1. Mass General Brigham Drops Weight-Loss GLP-1 Coverage for Some Staff; MPs Call NHS Mounjaro Plan 'Woefully Small'; CBS Tests Bootleg Retatrutide — October 23, 2026

    Mass General Brigham confirms affected employee plans will stop covering GLP-1s for weight loss on January 1, 2027, and British MPs say the NHS plan for Mounjaro reaches only about 6% of eligible people. CBS News lab-tested vials sold as retatrutide and found one held no peptide at all, plus...

  2. Judge Sends Zepbound Denial Suit to Arbitration; Telehealth Sells GLP-1s for Addiction; SOUL's Kidney Fine Print — October 22, 2026

    A Los Angeles judge sent a patient's lawsuit, which says Anthem cut off Zepbound because it worked, to private arbitration. Also today: telehealth companies offering GLP-1s off-label for addiction, and what the SOUL trial does and doesn't show about oral semaglutide and the kidneys. In this...

  3. Houston Pharmacy Recalls Compounded Tirzepatide After FDA Sterility Findings; Belgium Warns on Off-Label Use — October 21, 2026

    An FDA inspection report details 14 problems at Houston RX, the pharmacy behind a nationwide recall of compounded tirzepatide vials, while Belgium's medicines agency warns against off-label GLP-1 use and black-market retatrutide. Plus, Novo's company-reported CagriSema data in women ahead of an...

  4. FDA Blocks Two Chinese GLP-1 Ingredient Makers; Obesity-Drug Denials Get Harder to Beat — October 19, 2026

    FDA inspection reports describe mold, insects and hidden records at two Chinese suppliers of compounded semaglutide and tirzepatide ingredients, now on import alert. Plus a Health Affairs Scholar study on first-fill GLP-1 denials, and the EU drug regulator's committee backing Lilly's Foundayo…

    more

  5. Death Reports Name Bootleg Retatrutide; Walmart's Free GLP-1s Skip Weight Loss — October 14, 2026

    CBS News obtained two unverified FDA adverse-event reports of deaths after use of products sold as retatrutide, and Walmart will make Ozempic and Mounjaro free in 2027 for employees with type 2 diabetes but still won't cover GLP-1s for weight loss. Plus, a new Annals of Internal Medicine paper...

  6. Retatrutide Black Market Hits Before Approval; Wegovy Pill Generics Far Off — October 13, 2026

    Eli Lilly is moving against med spas and online sellers marketing its unapproved obesity drug retatrutide, which is still in phase 3. Separately, patent and bioequivalence hurdles suggest a generic Wegovy pill could be more than a decade away. In this episode: Top stories: 1. Lilly is fighting a...

  7. Wegovy Liver-Fat Data at EASD 2026, and What the Wegovy Pill Changes — October 12, 2026

    Novo Nordisk's post hoc STEP UP analysis at EASD 2026 says Wegovy brought liver fat below 5 percent in 23 of 26 adults with obesity. We weigh that small, company-presented result and what the oral Wegovy pill does and doesn't change for patients. In this episode: Top stories: 1. Wegovy reduced...

  8. Lilly's Oral GLP-1 Orforglipron Clears Heart-Safety Bar in ACHIEVE-4 — October 09, 2026

    Eli Lilly's once-daily oral GLP-1 orforglipron showed no excess cardiovascular risk against insulin glargine in the 2,749-patient ACHIEVE-4 trial, published in The Lancet. That clears a key regulatory hurdle, while an NEJM perspective warns that obesity drug trials aren't built to detect emerging...

  9. GLP-1 Users Lost Sight in the Second Eye Sooner, Ophthalmology Study Finds as Vision-Loss Lawsuits Grow — October 08, 2026

    An American Academy of Ophthalmology meeting study links GLP-1 use to faster second-eye NAION, as federal eye-injury cases climb to 247; plus Medicare Bridge paperwork gaps for cash-pay patients, pharmacists seeing more cash GLP-1 fills, the WHO's first childhood obesity guidelines, and Korea's...

  10. Medicare's $50 GLP-1 Bridge Leaves Out Some Sick Seniors — October 07, 2026

    Medicare's $50-a-month GLP-1 Bridge pilot is denying some obese seniors who have certain diagnoses, such as severe sleep apnea. Separately, Amylyx will present Phase 3 avexitide data for post-bariatric hypoglycemia at ObesityWeek in November. In this episode: Top stories: 1. Amylyx to Present…

    more

  11. Federal Plans Tie 2027 GLP-1 Coverage to Behavioral Therapy as Diabetes Guidelines Move GLP-1s Up Front — October 06, 2026

    Federal employee health plans will require documented intensive behavioral therapy before and during anti-obesity drug treatment in 2027, while the new ADA-EASD consensus backs GLP-1 or SGLT2 drugs early in type 2 diabetes. Plus a phase 3 oral GLP-1 pill, a new SELECT heart analysis, and what's...

  12. Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52% — October 05, 2026

    Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's...

  13. A $75 Copay Cliff for GLP-1 Adherence as New Mexico's Medicaid Ozempic Bill Climbs — October 02, 2026

    A JAMA Health Forum study finds GLP-1 nonadherence tops 80% once monthly out-of-pocket costs pass $75, while New Mexico's Medicaid Ozempic spending hit $38.7 million in 2025. Plus survodutide's Phase 3 in NEJM, the amylin tolerability tradeoff, and Novo's injection-to-pill switch data. In this...

  14. Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts — October 01, 2026

    Zepbound is back on CVS Caremark's standard commercial formulary starting October 1, but employers still decide, while Massachusetts critics press the state to undo its GLP-1 weight-loss coverage cuts. Plus a JAMA Health Forum Medicaid study on prior authorization, Lilly-sponsored ACHIEVE-4...

  15. Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD — September 30, 2026

    Counterfeit Ozempic allegedly sourced from China is at the center of a federal indictment of two Indian nationals in Tampa. At EASD in Milan, Lilly-funded Phase 3 retatrutide results appear in The Lancet, and a Novo-funded registry study finds no semaglutide–pancreatic cancer link. In this…

    more

  16. Zealand, Roche Start Petrelintide Phase 3 as 100% Pharma Tariffs Begin — September 29, 2026

    Zealand Pharma and Roche have launched a roughly 7,000-person Phase 3 program for once-weekly petrelintide in obesity. Meanwhile, a baseline 100 percent Section 232 tariff on imported patented medicines and ingredients takes effect and EASD convenes in Milan. In this episode: Top stories: 1.…

    more

  17. Mylan Tests Novo's Wegovy Patents as States Target Chinese GLP-1 Supply — September 28, 2026

    Mylan is asking a Delaware court to clear its proposed generic Wegovy from a new Novo Nordisk patent. Twenty state attorneys general are warning the White House about Chinese GLP-1 ingredient suppliers, and doctors are flagging a rare vision-loss risk still under study. In this episode: Top...

  18. Mounjaro Misuse in Japan, Contraband GLP-1 Pens Flood Brazil — September 25, 2026

    Mounjaro's off-label weight-loss use in Japan has drawn 35 suspected adverse-event reports, including pancreatitis and hypoglycemia. In Brazil, GLP-1 pen seizures in the first half of 2026 were 300% above all of 2025, as gray markets outpace regulated access. In this episode: Top stories: 1....

  19. Semaglutide heart signal meets FDA import and Medicare access shifts — September 24, 2026

    Semaglutide researchers say SELECT’s heart benefit isn’t fully explained by weight loss, but the practical GLP-1 fight is still access, from FDA import restrictions and Medicare Bridge uptake to Novo’s pipeline and oral manufacturing plans. Ask your prescriber before changing treatment. In this...

Type above to search every episode's transcript for a word or phrase. Matches are scoped to this podcast.

Searching…

We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.

No matches for "" in this podcast's transcripts.

Showing of matches

No topics indexed yet for this podcast.

Loading reviews...

ABOUT THIS SHOW

You're on a GLP-1 — or you're about to start one — and you don't have time to sift Facebook groups, press releases, and breathless headlines to figure out what actually changed today. GLP-1 Daily does that in eight minutes every weekday morning. Anchor Cassidy separates real label changes from pharma spin, while cohost Silvara tracks the cost and access story: prior authorization walls, employer-plan shifts, compounding-pharmacy enforcement, and who keeps getting left out of the semaglutide and tirzepatide conversation. We cover FDA decisions, clinical trial readouts, supply and shortage updates, and safety or side-effect news — everything framed around one question: does this change what you should ask your clinician today? Every efficacy figure is cited; company-reported data is flagged as such. We skip celebrity weight-loss content, before-and-after photos, and uncited miracle claims. If you take Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or any oral GLP-1 agonist, this is your

HOSTED BY

GLP-1 Daily — Lantern Podcasts

Frequently Asked Questions

How many episodes does GLP-1 Daily have?

GLP-1 Daily currently has 19 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.

What is GLP-1 Daily about?

You're on a GLP-1 — or you're about to start one — and you don't have time to sift Facebook groups, press releases, and breathless headlines to figure out what actually changed today. GLP-1 Daily does that in eight minutes every weekday morning. Anchor Cassidy separates real label changes from...

How often does GLP-1 Daily release new episodes?

GLP-1 Daily has 19 episodes. Check the episode list to see recent publication dates and frequency.

Where can I listen to GLP-1 Daily?

You can listen to GLP-1 Daily on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.

Who hosts GLP-1 Daily?

GLP-1 Daily is created and hosted by GLP-1 Daily — Lantern Podcasts.
URL copied to clipboard!